Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20

[PR Newswire] – SAN DIEGO, April 4, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee … more

View todays social media effects on HALO

View the latest stocks trending across Twitter. Click to view dashboard

See who Halozyme is hiring next, click here to view